Advancing delivery technologies for biologics and large molecules

The problem

Most animal health medicines are delivered systematically, leading to the need for larger doses, limited target range potential and off-target side effects.

The solution

Pioneering the next generation of macromolecule delivery technologies to unlock the full therapeutic potential of biologics, oligonucleotides, and other large molecules.

Our engagement

Anterra participated in Series A. Other investors include Lightsone Ventures and Jazz Ventures.